Back HIV/AIDS

HIV / AIDS

September 18 is National HIV/AIDS and Aging Awareness Day

This Wednesday, September 18, is the 6th observance of National HIV/AIDS and Aging Awareness Day (NHAAAD), an occasion to call attention to the epidemic's impact on older people, as well at the aging of people living with HIV in the U.S. According to the U.S. Department of Health and Human Services, approximately 30% of people living with HIV/AIDS are age 50 or older.

alt

ICAAC 2013: Researchers Present Data on New NNRTIs AIC292 and MK-1439

A pair of next-generation HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs) demonstrated promising activity in early studies, researchers reported last week at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver. AIC292 showed good antiviral activity in early laboratory, animal and human studies. MK-1439, now in Phase 2b, is likely to interact with ritonavir, but not tenofovir.

alt

ICAAC 2013: New Tenofovir Formulation Has Less Effect on Kidneys and Bones

Tenofovir alafenamide (TAF), a new formulation that reaches higher levels in cells but allows for lower dosing, was as effective as the current tenofovir disoproxil fumarate (TDF) formulation but had less impact on markers of kidney function and bone turnover, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver.

alt

ICAAC 2013: Dolutegravir Shows Good Efficacy Across Patient Groups

The new integrase inhibitor dolutegravir (Tivicay) worked better than boosted darunavir for people starting HIV treatment for the first time, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) last week in Denver. Another study found that dolutegravir worked well across sex, race/ethnicity, and age groups.

alt

Coverage of 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy

HIVandHepatitis.com coverage of the 53nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver, September 9-13, 2013.

Highlights of this year's meeting include experimental antiretroviral drugs and treatment strategies, CD4 cell gene therapy, HIV/HCV coinfection, liver transplants for people with HIV, and other sexually transmitted infections.

Full listing by topic

HIVandHepatitis.com ICAAC 2013 conference section

9/13/13

alt

ICAAC 2013: Depression Linked to Detectable HIV in Cerebrospinal Fluid

People who experience episodes of major depressive disorder (MDD) are significantly more likely to have detectable HIV in their cerebral-spinal fluid (CSF), according to an analysis of the large CHARTER study presented as a late-breaker poster at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) last week in Denver.

alt

ICAAC 2013: Raltegravir Safest for HIV+ Patients on Cancer Chemotherapy

The integrase inhibitor raltegravir (Isentress) may be an optimal choice for many HIV positive people undergoing cancer chemotherapy, as it is highly effective and well-tolerated in this population, according to a poster presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver.

alt